280 related articles for article (PubMed ID: 12944401)
21. Osteoclast differentiation by RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6).
Ogasawara T; Katagiri M; Yamamoto A; Hoshi K; Takato T; Nakamura K; Tanaka S; Okayama H; Kawaguchi H
J Bone Miner Res; 2004 Jul; 19(7):1128-36. PubMed ID: 15176996
[TBL] [Abstract][Full Text] [Related]
22. The generation of highly enriched osteoclast-lineage cell populations.
Quinn JM; Whitty GA; Byrne RJ; Gillespie MT; Hamilton JA
Bone; 2002 Jan; 30(1):164-70. PubMed ID: 11792580
[TBL] [Abstract][Full Text] [Related]
23. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.
Kimachi K; Kajiya H; Nakayama S; Ikebe T; Okabe K
Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):297-308. PubMed ID: 21225243
[TBL] [Abstract][Full Text] [Related]
24. Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts.
Kim HJ; Ohk B; Yoon HJ; Kang WY; Seong SJ; Kim SY; Yoon YR
Cell Signal; 2017 Jan; 29():226-232. PubMed ID: 27836739
[TBL] [Abstract][Full Text] [Related]
25. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor.
Huber DM; Bendixen AC; Pathrose P; Srivastava S; Dienger KM; Shevde NK; Pike JW
Endocrinology; 2001 Sep; 142(9):3800-8. PubMed ID: 11517156
[TBL] [Abstract][Full Text] [Related]
26. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
27. Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis.
Zhang Z; Jimi E; Bothwell AL
J Immunol; 2003 Oct; 171(7):3620-6. PubMed ID: 14500659
[TBL] [Abstract][Full Text] [Related]
28. Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity.
Conaway HH; Henning P; Lie A; Tuckermann J; Lerner UH
Bone; 2016 Dec; 93():43-54. PubMed ID: 27596806
[TBL] [Abstract][Full Text] [Related]
29. TGF-beta 1 and IFN-gamma direct macrophage activation by TNF-alpha to osteoclastic or cytocidal phenotype.
Fox SW; Fuller K; Bayley KE; Lean JM; Chambers TJ
J Immunol; 2000 Nov; 165(9):4957-63. PubMed ID: 11046022
[TBL] [Abstract][Full Text] [Related]
30. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
[TBL] [Abstract][Full Text] [Related]
31. RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKL-induced interferon-beta via NF-kappaB that restrains osteoclastogenesis and bone resorption.
Zheng H; Yu X; Collin-Osdoby P; Osdoby P
J Biol Chem; 2006 Jun; 281(23):15809-20. PubMed ID: 16613848
[TBL] [Abstract][Full Text] [Related]
32. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
33. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism.
Zou W; Hakim I; Tschoep K; Endres S; Bar-Shavit Z
J Cell Biochem; 2001 Jun 26-Jul 25; 83(1):70-83. PubMed ID: 11500955
[TBL] [Abstract][Full Text] [Related]
34. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages.
Rahman MM; Kukita A; Kukita T; Shobuike T; Nakamura T; Kohashi O
Blood; 2003 May; 101(9):3451-9. PubMed ID: 12511413
[TBL] [Abstract][Full Text] [Related]
35. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
[TBL] [Abstract][Full Text] [Related]
36. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
37. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
38. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
39. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways.
Zhang YH; Heulsmann A; Tondravi MM; Mukherjee A; Abu-Amer Y
J Biol Chem; 2001 Jan; 276(1):563-8. PubMed ID: 11032840
[TBL] [Abstract][Full Text] [Related]
40. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression.
Karsdal MA; Hjorth P; Henriksen K; Kirkegaard T; Nielsen KL; Lou H; Delaissé JM; Foged NT
J Biol Chem; 2003 Nov; 278(45):44975-87. PubMed ID: 12933809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]